Exhibit 10.2

 

EXECUTION VERSION

 

EX-U.S. TRANSITION SERVICES AGREEMENT

 

BY AND BETWEEN

 

ABBOTT LABORATORIES

 

AND

 

ABBVIE INC.

 

DATED AS OF DECEMBER 31, 2012

 











 

TABLE OF CONTENTS

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
ARTICLE   I
    	
DEFINITIONS
    	
1
    
	
 
    	
 
    	
 
    
	
Section 1.01.
    	
Definitions
    	
1
    
	
 
    	
 
    	
 
    
	
ARTICLE   II
    	
SERVICES
    	
4
    
	
 
    	
 
    	
 
    
	
Section 2.01.
    	
Initial Services
    	
4
    
	
Section 2.02.
    	
Omitted Services; Excluded Services; Additional   Services
    	
4
    
	
Section 2.03.
    	
Performance of Services
    	
6
    
	
Section 2.04.
    	
Charges for Services
    	
7
    
	
Section 2.05.
    	
Reimbursement for Out-of-Pocket Expenses
    	
8
    
	
Section 2.06.
    	
Changes to Services
    	
8
    
	
Section 2.07.
    	
Transitional Nature of Services
    	
8
    
	
Section 2.08.
    	
Use of Third Parties to Provide Services
    	
9
    
	
Section 2.09.
    	
Joinder Agreement
    	
9
    
	
 
    	
 
    	
 
    
	
ARTICLE   III
    	
OTHER   ARRANGEMENTS
    	
10
    
	
 
    	
 
    	
 
    
	
Section 3.01.
    	
Access
    	
10
    
	
 
    	
 
    	
 
    
	
ARTICLE   IV
    	
BILLING;   TAXES
    	
11
    
	
 
    	
 
    	
 
    
	
Section 4.01.
    	
Procedure
    	
11
    
	
Section 4.02.
    	
Late Payments
    	
11
    
	
Section 4.03.
    	
Taxes
    	
11
    
	
Section 4.04.
    	
No Set-Off
    	
11
    
	
 
    	
 
    	
 
    
	
ARTICLE   V
    	
TERM   AND TERMINATION
    	
11
    
	
 
    	
 
    	
 
    
	
Section 5.01.
    	
Term
    	
11
    
	
Section 5.02.
    	
Early Termination
    	
12
    
	
Section 5.03.
    	
Reduction of Services
    	
12
    
	
Section 5.04.
    	
Extension of Services
    	
13
    
	
Section 5.05.
    	
Interdependencies
    	
14
    
	
Section 5.06.
    	
Effect of Termination
    	
14
    
	
Section 5.07.
    	
Information Transmission
    	
15
    
	
 
    	
 
    	
 
    
	
ARTICLE   VI
    	
CONFIDENTIALITY;   PROTECTIVE ARRANGEMENTS
    	
15
    
	
 
    	
 
    	
 
    
	
Section 6.01.
    	
Abbott and AbbVie Obligations
    	
15
    
	
Section 6.02.
    	
No Release
    	
16
    
	
Section 6.03.
    	
Third Party Information; Privacy and Data   Protection Laws
    	
16
    
	
Section 6.04.
    	
Protective Arrangements
    	
16
    


 

i











 

TABLE OF CONTENTS
 (continued)

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
ARTICLE   VII
    	
LIMITED   LIABILITY AND INDEMNIFICATION
    	
17
    
	
 
    	
 
    	
 
    
	
Section 7.01.
    	
Limitations on Liability
    	
17
    
	
Section 7.02.
    	
Obligation to Re-Perform; Liabilities
    	
17
    
	
Section 7.03.
    	
Third Party Claims
    	
18
    
	
Section 7.04.
    	
Indemnification Procedures
    	
18
    
	
 
    	
 
    	
 
    
	
ARTICLE   VIII
    	
TRANSITION   COMMITTEE; ABBOTT AND ABBVIE RIGHTS
    	
18
    
	
 
    	
 
    	
 
    
	
Section 8.01.
    	
Establishment
    	
18
    
	
Section 8.02.
    	
Rights of Abbott and AbbVie
    	
18
    
	
 
    	
 
    	
 
    
	
ARTICLE   IX
    	
MISCELLANEOUS
    	
18
    
	
 
    	
 
    	
 
    
	
Section 9.01.
    	
Mutual Cooperation
    	
18
    
	
Section 9.02.
    	
Title to Intellectual Property
    	
18
    
	
Section 9.03.
    	
Force Majeure
    	
19
    
	
Section 9.04.
    	
Independent Contractors
    	
19
    
	
Section 9.05.
    	
Third Party Beneficiaries
    	
19
    
	
Section 9.06.
    	
Governing Law
    	
20
    
	
Section 9.07.
    	
Dispute Resolution
    	
20
    
	
Section 9.08.
    	
Specific Performance
    	
20
    
	
Section 9.09.
    	
Interpretation
    	
20
    
	
Section 9.10.
    	
Headings
    	
21
    
	
Section 9.11.
    	
Amendment
    	
21
    
	
Section 9.12.
    	
Assignability
    	
21
    
	
Section 9.13.
    	
Audit Assistance
    	
21
    
	
Section 9.14.
    	
Survival of Covenants
    	
22
    
	
Section 9.15.
    	
Subsidiaries
    	
22
    
	
Section 9.16.
    	
Waivers of Default
    	
22
    
	
Section 9.17.
    	
Notices
    	
22
    
	
Section 9.18.
    	
Counterparts
    	
23
    
	
Section 9.19.
    	
Entire Agreement
    	
23
    
	
Section 9.20.
    	
Corporate Power
    	
23
    
	
Section 9.21.
    	
Signatures and Delivery
    	
23
    
	
Section 9.22.
    	
Severability
    	
23
    


 

ii











 

TABLE OF CONTENTS
 (continued)

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
Section 9.23.
    	
Attorney-in-Fact
    	
24
    
	
Section 9.24.
    	
Further Assurances
    	
24
    
	
Section 9.25.
    	
Public Announcements
    	
25
    
	
Section 9.26.
    	
Mutual Drafting
    	
25
    


 

iii











 

EXHIBITS

 

	
Exhibit   A-1
    	
Other   Manufacturing Costs
    	
 
    
	
Exhibit   A-2
    	
Quality   Assurance
    	
 
    
	
Exhibit   A-3
    	
Distribution   — Order Entry
    	
 
    
	
Exhibit   A-4
    	
Distribution   — Warehousing
    	
 
    
	
Exhibit   A-5
    	
Other   Charges to COGS
    	
 
    
	
Exhibit   A-6
    	
Regulatory   Affairs
    	
 
    
	
Exhibit   A-7
    	
Medical   Affairs
    	
 
    
	
Exhibit   A-8
    	
Pharmacovigilance
    	
 
    
	
Exhibit   A-9
    	
Development
    	
 
    
	
Exhibit   A-10
    	
Other   R&D / Medical
    	
 
    
	
Exhibit   A-11
    	
Advertising   / Marketing
    	
 
    
	
Exhibit   A-12
    	
Sales   Force Support
    	
 
    
	
Exhibit   A-13
    	
Accounting,   Reporting & Financial Services
    	
 
    
	
Exhibit   A-14
    	
Financial   Planning & Analysis
    	
 
    
	
Exhibit   A-15
    	
Information   Technology
    	
 
    
	
Exhibit   A-16
    	
Office   Space, Facilities & Related
    	
 
    
	
Exhibit   A-17
    	
Other   General Administration
    	
 
    
	
Exhibit   B
    	
Omitted   Services/Additional Services Template
    	
 
    
	
Exhibit   C
    	
Form   of Joinder Agreement
    	
 
    


 

iv











 

THIS EX-U.S. TRANSITION SERVICES AGREEMENT, dated as of December 31, 2012, is by and between ABBOTT LABORATORIES, an Illinois corporation (“Abbott”) and ABBVIE INC., a Delaware corporation (“AbbVie”), and each of their respective Subsidiaries (as defined herein) who execute a Joinder Agreement (as defined herein) in accordance with the terms and provisions of this Agreement (as defined herein).

 

R E C I T A L S:

 

WHEREAS, the board of directors of Abbott has determined that it is appropriate and advisable to separate Abbott’s research-based pharmaceuticals business from its other businesses;

 

WHEREAS, in order to effectuate the foregoing, Abbott and AbbVie have entered into a Separation and Distribution Agreement, dated as of November 28, 2012 (the “Separation and Distribution Agreement”), which provides for, among other things, the contribution from Abbott to AbbVie of certain assets, the assumption by AbbVie of certain Liabilities (as defined in the Separation and Distribution Agreement) from Abbott, the distribution by Abbott of AbbVie common stock to Abbott shareholders, and the execution and delivery of certain agreements in order to facilitate and provide for the foregoing, in each case subject to the terms and conditions set forth therein; and

 

WHEREAS, in order to facilitate and provide for an orderly transition under the Separation and Distribution Agreement, the Parties desire to enter into this Agreement to set forth the terms and conditions pursuant to which each Provider (as defined herein) shall provide to the applicable Recipient (as defined herein) the Services (as defined herein) for a transitional period.

 

NOW, THEREFORE, in consideration of the mutual agreements, provisions and covenants contained in this Agreement, the Parties (as defined herein) hereby agree as follows:

 

ARTICLE I

 

DEFINITIONS

 

Section 1.01.                          Definitions.  Reference is made to Section 9.09 regarding the interpretation of certain words and phrases used in this Agreement.  In addition, for the purpose of this Agreement, the following terms shall have the meanings set forth below; provided that where such term is defined to have the meaning set forth in the Separation and Distribution Agreement and such definition includes the term “Party”, then “Party” as used in the definition of such term in the Separation and Distribution Agreement shall be construed to have the meaning set forth in this Agreement.

 

“Abbott” has the meaning set forth in the Preamble.

 

“Abbott Subsidiary” has the meaning set forth in the Separation and Distribution Agreement.

 

“AbbVie” has the meaning set forth in the Preamble.

 

1











 

“AbbVie Business” has the meaning set forth in the Separation and Distribution Agreement.

 

“AbbVie Subsidiary” has the meaning set forth in the Separation and Distribution Agreement.

 

“Accounting, Reporting & Financial Services” has the meaning set forth in Section 5.04(c).

 

“Additional Service” has the meaning set forth in Section 2.02(c).

 

“Affiliate” has the meaning set forth in the Separation and Distribution Agreement.

 

“Agreement” means this Ex-U.S. Transition Services Agreement, each of the Schedules and Exhibits hereto and each Joinder Agreement executed in accordance with Section 2.09.

 

“ARF Service Period End Date” has the meaning set forth in Section 5.04(c).

 

“Change of Control” has the meaning set forth in the Separation and Distribution Agreement.

 

“Charges” has the meaning set forth in Section 2.04.

 

“Collection Service” has the meaning set forth in Section 5.04(c).

 

“Commencement Date” means, with respect to a given Recipient and the applicable Provider, the date set forth under the heading “Commencement Date” on Schedule 1 to the applicable Joinder Agreement executed by such Recipient and the applicable Provider.

 

“Dispute” has the meaning set forth in Section 9.07(a).

 

“Effective Time” has the meaning set forth in the Separation and Distribution Agreement.

 

“Excluded Service” has the meaning set forth in Section 2.02(b).

 

“Force Majeure” has the meaning set forth in the Separation and Distribution Agreement.

 

“Governmental Authority” has the meaning set forth in the Separation and Distribution Agreement.

 

“Information” has the meaning set forth in the Separation and Distribution Agreement.

 

“Initial Services” has the meaning set forth in Section 2.01.

 

2











 

“Interest Payment” has the meaning set forth in Section 4.02.

 

“Joinder Agreement” has the meaning set forth in Section 2.09.

 

“Law” has the meaning set forth in the Separation and Distribution Agreement.

 

“Liabilities” has the meaning set forth in the Separation and Distribution Agreement.

 

“Notice” means any written notice, request, demand or other communication specifically referencing this Agreement and given in accordance with Section 9.17.

 

“Omitted Service” has the meaning set forth in Section 2.02(a).

 

“Parties” means Abbott and the Abbott Subsidiaries who execute a Joinder Agreement pursuant to Section 2.09, on the one hand, and AbbVie and the AbbVie Subsidiaries who execute a Joinder Agreement pursuant to Section 2.09, on the other hand.

 

“Person” has the meaning set forth in the Separation and Distribution Agreement.

 

“Personal Data” means data that can be used by itself or in combination with other available data to identify a specific individual.

 

“Prime Rate” has the meaning set forth in the Separation and Distribution Agreement.

 

“Privileged Information” has the meaning set forth in the Separation and Distribution Agreement.

 

“Proceeding” has the meaning set forth in the Separation and Distribution Agreement.

 

“Provider” means, with respect to any Service, the Affiliate or Affiliates of Abbott or AbbVie who have executed a Joinder Agreement and is or are identified therein as the “Provider,” or Abbott or AbbVie, as the case may be, if they are identified as the “Provider” in any Joinder Agreement.

 

“Provider Indemnitees” has the meaning set forth in Section 7.03.

 

“Recipient” means, with respect to any Service, the Affiliate or Affiliates of Abbott or AbbVie who have executed a Joinder Agreement and is or are identified therein as the “Recipient,” or Abbott or AbbVie, as the case may be, if they are identified as the “Recipient” in any Joinder Agreement.

 

“Reinstated Service” has the meaning set forth in Section 2.02(b).

 

“Representatives” has the meaning set forth in the Separation and Distribution Agreement.

 

3











 

“Separation and Distribution Agreement” has the meaning set forth in the Recitals.

 

“Service Baseline Period” has the meaning set forth in Section 2.03(c).

 

“Service Extension” has the meaning set forth in Section 5.04(a).

 

“Service Period” means, with respect to any Service provided to a given Recipient, the period commencing on the later of (a) the Commencement Date for such Service and (b) the date on which any Omitted Service, Excluded Service or Additional Service becomes a “Service” pursuant to the terms of this Agreement, and ending on the earlier of (i) the date the Recipient terminates the provision of such Service pursuant to Section 5.02 and (ii) the second anniversary of the Effective Time, unless extended pursuant to Section 5.04.

 

“Services” means, with respect to a given Recipient, the Initial Services and the applicable Omitted Services, Reinstated Services and Additional Services for such Recipient.

 

“Subsidiary” has the meaning set forth in the Separation and Distribution Agreement.

 

“Tax” has the meaning set forth in the Separation and Distribution Agreement.

 

“Tax Authority” has the meaning set forth in the Separation and Distribution Agreement.

 

“Third Party” has the meaning set forth in the Separation and Distribution Agreement.

 

“Transition Committee” has the meaning set forth in the Separation and Distribution Agreement.

 

ARTICLE II

 

SERVICES

 

Section 2.01.                          Initial Services.  Effective as of the commencement of the Service Period, the applicable Provider shall provide, or Abbott or AbbVie, as applicable, shall cause one or more of its other Subsidiaries to provide, to the applicable Recipient, the services (the “Initial Services”) for which a Commencement Date is indicated on Schedule 1 of the applicable Joinder Agreement for such Recipient and as described in greater detail on the subsections of Exhibit A hereto.

 

Section 2.02.                          Omitted Services; Excluded Services; Additional Services.

 

(a)                                 If, following the Effective Time and during the term of this Agreement, a Recipient identifies a service that, prior to the Effective Time, its applicable Provider or any of its Subsidiaries provided to such Recipient, but such service was inadvertently omitted from the Services set forth on Schedule 1 of the applicable Joinder Agreement (each such service, an

 

4











 

“Omitted Service”), then such Provider shall use commercially reasonable efforts to provide, or to cause one of its Subsidiaries to provide, any such Omitted Service to such Recipient; provided that such Provider shall not be obligated to provide any Omitted Service if it does not, in its reasonable judgment, have adequate resources to provide such Omitted Service or if the provision of such Omitted Service would significantly disrupt the operation of its businesses.  Abbott and AbbVie shall cooperate and act in good faith to create a supplemental subsection of Exhibit A hereto for each Omitted Service in the form attached hereto as Exhibit B.  The applicable Provider and Recipient shall (i) amend Schedule 1 of the applicable Joinder Agreement to include such Omitted Service and (ii) promptly provide Notice of such amendment (including a copy thereof) to Abbott and AbbVie.  Each such supplemental subsection of Exhibit A hereto and each such amended Schedule 1 to such Joinder Agreement  shall be deemed part of this Agreement as of the date of such agreement and the Omitted Services set forth therein shall be deemed “Services” provided under this Agreement, in each case subject to the terms and conditions of this Agreement.

 

(b)                                 If, following the Effective Time and during the term of this Agreement, a Recipient identifies a service that, prior to the Effective Time, its applicable Provider or any of its Subsidiaries provided to such Recipient, but Abbott and AbbVie had mutually agreed that such service would not be provided under the terms of this Agreement (each such service, an “Excluded Service”), then such Recipient or Provider shall provide Notice thereof to Abbott and AbbVie, and Abbott and AbbVie shall cooperate and act in good faith to determine whether such Provider shall provide such Excluded Service to such Recipient under the terms of this Agreement.  If Abbott and AbbVie determine that such Provider shall provide such Excluded Service to such Recipient (each such Excluded Service, a “Reinstated Service”), then Abbott and AbbVie will act in good faith to create a supplemental subsection of Exhibit A hereto for each Reinstated Service in the form attached hereto as Exhibit B.  The applicable Provider and Recipient shall (i) amend Schedule 1 of the applicable Joinder Agreement to include such Reinstated Service and (ii) promptly provide Notice of such amendment (including a copy thereof) to Abbott and AbbVie.  Each such supplemental subsection of Exhibit A hereto and each such amended Schedule 1 to such Joinder Agreement shall be deemed part of this Agreement as of the date of such agreement and the Reinstated Services set forth therein shall be deemed “Services” provided under this Agreement, in each case subject to the terms and conditions of this Agreement.

 

(c)                                  If, following the Effective Time and during the term of this Agreement, a Recipient identifies a service, other than an Omitted Service or an Excluded Service, that it desires for its applicable Provider or any of its Subsidiaries to provide to such Recipient (each such service, an “Additional Service”), then such Provider shall consider such request, in conjunction with Abbott and AbbVie; provided  that nothing shall require such Provider to provide such Additional Service to such Recipient.  If such Provider consents to providing an Additional Service to such Recipient, then such Recipient or Provider shall provide Notice thereof to Abbott and AbbVie, and Abbott and AbbVie shall cooperate and act in good faith to create a  supplemental subsection of Exhibit A hereto for each Additional Service in the form attached hereto as Exhibit B.  The applicable Provider and Recipient shall (i) amend Schedule 1 of the applicable Joinder Agreement to include such Additional Service and (ii) promptly provide Notice of such amendment (including a copy thereof) to Abbott and AbbVie.  Each such supplemental subsection of Exhibit A hereto and each such amended Schedule 1 to such Joinder

 

5









 

Agreement shall be deemed part of this Agreement as of the date of such agreement and the Additional Services set forth therein shall be deemed “Services” provided under this Agreement, in each case subject to the terms and conditions of this Agreement.

 

Section 2.03.                          Performance of Services.

 

(a)                                 Each Provider shall perform and cause its Subsidiaries to perform all Services to be provided by such Provider in a manner that is based on its past practice and that is substantially similar in nature, quality and timeliness to the analogous services provided by Abbott to the Abbott Subsidiaries prior to the Commencement Date.  Each Provider shall, and shall cause its Subsidiaries to, perform its duties and responsibilities hereunder in good faith.

 

(b)                                 Nothing in this Agreement shall require a Provider to perform or cause to be performed any Service to the extent the manner of such performance would constitute a violation of applicable Laws, the Abbott Code of Business Conduct or any existing contract or agreement with a Third Party.  If a Provider is or becomes aware of any potential violation on the part of the Provider, such Provider shall use commercially reasonable efforts to promptly send a Notice to its applicable Recipient of such potential violation.  Each Provider and Recipient agrees to cooperate and use commercially reasonable efforts to obtain any necessary Third Party consents required under any existing contract or agreement with a Third Party to allow the applicable Provider to perform or cause to be performed any Service in accordance with the standards set forth in this Section 2.03.  Any costs and expenses incurred by any Provider or Recipient or any of its respective Subsidiaries in connection with obtaining any such Third Party consent that is required to allow the applicable Provider to perform or cause to be performed (i) any Service (other than an Additional Service) shall be split between the applicable Provider and Recipient in accordance with such Parties’ respective utilization of the applicable Service at such time (except with respect to fees imposed by Third Parties to allow joint participation by the Provider and the Recipient under information technology contracts and licenses, which fees shall be split equally between the applicable Provider and the Recipient) and (ii) any Additional Service shall be solely the responsibility of the Recipient.  If, with respect to a Service, the applicable Provider and Recipient, despite the use of such commercially reasonable efforts, are unable to obtain a required Third Party consent or the performance of such Service by the applicable Provider would continue to constitute a violation of applicable Laws or the Abbott Code of Business Conduct, the applicable Provider shall use commercially reasonable efforts in good faith to provide such Services in a manner as closely as possible to the standards described in this Section 2.03 that would apply absent the exception provided for in the first sentence of this Section 2.03(b).

 

(c)                                  No Provider shall be obligated to perform or to cause to be performed any Service in a volume or quantity in any calendar year that exceeds the highest volumes or quantities of analogous services provided to the applicable Recipient during calendar year 2012, as set forth in the 2012 plan (without reference to the transactions contemplated by the Separation and Distribution Agreement) (the “Service Baseline Period”).  If a Recipient requests that its Provider perform or cause to be performed any Service in a volume or quantity that exceeds the highest volumes or quantities of analogous services that were provided to such Recipient during the Service Baseline Period, then: (i) if such higher volume or quantity results from fluctuations occurring in the ordinary course of business of such Recipient, the applicable

 

6











 

Provider shall use commercially reasonable efforts to provide such requested higher volume or quantity; and (ii) if such higher volume or quantity results from any other source, including an acquisition, merger, purchase or other business combination by such Recipient, then such Recipient or Provider shall provide Notice thereof to Abbott and AbbVie, and Abbott and AbbVie shall cooperate and act in good faith to determine whether the applicable Provider will be required to provide such requested higher volume or quantity.  If Abbott and AbbVie determine that the applicable Provider shall provide the requested higher volume or quantity then such higher volume or quantity shall be documented in a written agreement signed by the applicable Recipient and Provider who shall promptly provide Notice of such agreement (including a copy thereof) to Abbott and AbbVie.  The volume or quantity increases set forth in such written agreement shall be deemed a part of the “Services” provided under this Agreement, in each case subject to the terms and conditions of this Agreement.

 

(d)                                 (i) No Provider or any of its Subsidiaries shall be required to perform or to cause to be performed any of the Services for the benefit of any Third Party or any other Person other than the applicable Recipient, and (ii) EXCEPT AS EXPRESSLY PROVIDED IN THIS SECTION 2.03, EACH PARTY ACKNOWLEDGES AND AGREES THAT ALL SERVICES AND PRODUCTS ARE PROVIDED ON AN “AS IS” BASIS, THAT EACH RECIPIENT ASSUMES ALL RISK AND LIABILITY ARISING FROM OR RELATING TO ITS USE OF AND RELIANCE UPON THE SERVICES, AND THAT EACH PROVIDER MAKES NO OTHER REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, WITH RESPECT TO THE SERVICES AND PRODUCTS.  EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

 

(e)                                  Each Party shall be responsible for its own compliance with any and all Laws applicable to its performance under this Agreement.  No Party shall knowingly take any action in violation of any such applicable Law that results in Liability being imposed on any other Party.

 

Section 2.04.                          Charges for Services.  Each Recipient shall pay to its applicable Provider a monthly fee for the Services (or category of Services, as applicable) (each fee constituting a “Charge” and, collectively, “Charges”) provided by such Provider or its applicable Subsidiaries, which Charges shall be agreed to by the applicable Provider and Recipient from time to time.  During the term of this Agreement, the amount of a Charge for any Services may adjust to the extent of:  (a) any adjustments mutually agreed to by the applicable Provider and Recipient; (b) any Charges applicable to any Omitted Services, Reinstated Services or Additional Services; and (c) in accordance with Section 2.08, any proportional adjustment in the rates or charges imposed by any Third Party provider that is providing Services.  Together with any monthly invoice for Charges, each Provider shall provide its applicable Recipient with reasonable documentation, including any additional documentation reasonably requested by such Recipient to the extent such documentation is in such Provider’s or its Subsidiaries’ possession or control, to support the calculation of such Charges.

 

7











 

Section 2.05.                          Reimbursement for Out-of-Pocket Expenses.  Each Recipient shall reimburse its applicable Provider for reasonable out-of-pocket costs and expenses incurred by such Provider or any of its Subsidiaries in connection with providing the Services (including reasonable travel-related expenses) to the extent that such costs and expenses are not reflected in the Charges for such Services; provided, however, that any such cost or expense not consistent with historical practice between such Provider and Recipient for any Service (including business travel and related expenses) shall require advance approval of such Recipient.  Any authorized travel-related expenses incurred in performing the Services shall be incurred and charged to the applicable Recipient in accordance with such Provider’s then applicable business travel policies.

 

Section 2.06.                          Changes to Services.

 

(a)                                 Except as provided in Section 2.08 and subject to the performance standards set forth in this Article II, each Provider may make changes from time to time in the manner of performing the Services if such Provider is making similar changes in performing analogous services for itself and if such Provider furnishes to its applicable Recipient reasonable prior Notice (in content and timing) respecting such changes; provided, however, that no Provider may modify any of its accounting policies or its foreign exchange rate setting process as defined in the B.2.0 policy that would directly or indirectly impact the Services without the prior written consent of its applicable Recipient (such consent not to be unreasonably withheld or delayed).  No such change shall affect the timeliness or quality of, or the Charges for, the applicable Service.  If any such change by a Provider reasonably requires its applicable Recipient to incur incremental costs and expenses in order to continue to receive and utilize the applicable Services in the same manner as such Recipient was receiving and utilizing such Service prior to such change, such Provider shall be required to reimburse such Recipient for all such reasonable costs and expenses.  Upon request of a Provider, the applicable Recipient shall provide such Provider with reasonable documentation, including any additional documentation reasonably requested by such Provider to the extent such documentation is in such Recipient’s or its Subsidiaries’ possession or control, to support the calculation of such incremental costs and expenses.

 

(b)                                 AbbVie acknowledges that it has received a copy of Abbott’s B.2.0 internal calendar for 2013 from Abbott. Prior to the commencement of each subsequent calendar year during the term of this Agreement, Abbott shall make available to AbbVie a copy of Abbott’s B.2.0 internal calendar for such calendar year (and AbbVie may request the same of Abbott if Abbott has not made such copy available to AbbVie prior to the commencement of the applicable subsequent calendar year).

 

(c)                                  Prior to 12:00 p.m. Central Time on the B.2.0 day of each calendar month during the term of this Agreement, Abbott shall make available to AbbVie a copy of Abbott’s foreign exchange rates determined in accordance with Abbott’s B.2.0 policy for such calendar month (and AbbVie may request the same of Abbott if Abbott has not made such copy available to AbbVie prior to 12:00 p.m. Central Time on the B.2.0 day of the applicable calendar month).

 

Section 2.07.                          Transitional Nature of Services.  Each Provider and applicable Recipient acknowledge the transitional nature of the Services and agree to cooperate in good faith and to

 

8











 

use commercially reasonable efforts to effectuate a smooth transition of the Services from such Provider to such Recipient (or its designee).

 

Section 2.08.                          Use of Third Parties to Provide Services.  Each Provider may perform its obligations to provide a Service through agents, subcontractors or independent contractors, provided that the delegation of performance of the applicable Service does not impact the timeliness or quality of such Service, in accordance with the following:

 

(a)                                 Provider is Currently Using Third Parties as of the Effective Time.  If, as of the Effective Time, (i) the Provider is obtaining analogous services for itself from agents, subcontractors or independent contractors, or (ii) the Provider is obtaining services from agents, subcontractors or independent contractors which services such Provider shall only provide to its applicable Recipient under this Agreement and such Provider shall not otherwise require such analogous services for itself during the term of this Agreement, then the Charges for the applicable Services such Provider is obtaining from such Third Parties may be adjusted proportionally by such Provider pursuant to Section 2.04(c) to reflect any adjustment in the rates or charges imposed by the Third Party that is providing such Services; or

 

(b)                                 Provider Elects to Switch to Third Parties After the Effective Time.

 

(i)                                     If, following the Effective Time, the Provider elects to obtain analogous services for itself from agents, subcontractors or independent contractors (A) such Provider shall furnish to its applicable Recipient reasonable prior Notice (in content and timing) respecting such use of Third Parties, and (B) the Charges for the applicable Services such Provider is obtaining from such Third Parties may be adjusted proportionally by such Provider pursuant to Section 2.04(c) to reflect any adjustment in the rates or charges imposed by the Third Party that is providing such Services; and

 

(ii)                                  If, however, following the Effective Time, the Provider is not obtaining analogous services for itself from agents, subcontractors or independent contractors (A) such Provider shall furnish to its applicable Recipient reasonable prior Notice (in content and timing) respecting such use of Third Parties, and (B) the Charges for the applicable Services such Provider is providing through such Third Parties appointed following the Effective Time may not be adjusted by such Provider as a result of any adjustments in the rates or charges imposed by such Third Parties.

 

Notwithstanding the foregoing, no Provider shall be relieved of its obligations under this Agreement by use of such agents, subcontractors or independent contractors.

 

Section 2.09.                          Joinder Agreement.  Each of Abbott and AbbVie shall cause their respective Subsidiaries who are to provide or receive Services to become a party to this Agreement and adopt this Agreement with the same force and effect as if it were originally a party hereto by executing a Joinder Agreement substantially in the form attached as Exhibit C hereto (each, a “Joinder Agreement”).  Each such Joinder Agreement executed pursuant to this Section 2.09 shall be deemed part of this Agreement as of the date of such Joinder Agreement.

 

9











 

ARTICLE III

 

OTHER ARRANGEMENTS

 

Section 3.01.                          Access.

 

(a)                                 AbbVie shall, and shall cause its Subsidiaries to, allow Abbott and its Subsidiaries and their respective Representatives reasonable access to the facilities of AbbVie and its Subsidiaries that is necessary for Abbott and its Subsidiaries to fulfill their obligations under this Agreement.  In addition to the foregoing right of access, AbbVie shall, and shall cause its Subsidiaries to, afford Abbott, its Subsidiaries and their respective Representatives, upon reasonable advance notice, reasonable access during normal business hours to the facilities, Information, systems, infrastructure and personnel of AbbVie and its Subsidiaries as reasonably necessary for Abbott to verify the adequacy of internal controls over information technology, reporting of financial data and related processes employed in connection with the Services being provided by AbbVie or its Subsidiaries, including in connection with verifying compliance with Section 404 of the Sarbanes-Oxley Act of 2002; provided that (i) such access shall not unreasonably interfere with any of the business or operations of AbbVie or any of its Subsidiaries and (ii) in the event that AbbVie determines that providing such access could be commercially detrimental, violate any Law or agreement, or waive any attorney-client privilege, then Abbott and AbbVie shall use commercially reasonable efforts to permit such access in a manner that avoids any such harm or consequence.  Abbott agrees that all of its and its Subsidiaries’ employees shall, and that it shall use commercially reasonable efforts to cause its Representatives’ employees to, when on the property of AbbVie and its Subsidiaries, or when given access to any facilities, Information, systems, infrastructure or personnel of AbbVie and its Subsidiaries, conform to the policies and procedures of AbbVie and any of its Subsidiaries, as applicable, concerning health, safety, conduct and security which are made known to Abbott from time to time.

 

(b)                                 Abbott shall, and shall cause its Subsidiaries to, allow AbbVie and its Subsidiaries and their respective Representatives reasonable access to the facilities of Abbott and its Subsidiaries that is necessary for AbbVie and its Subsidiaries to fulfill their obligations under this Agreement.  In addition to the foregoing right of access, Abbott shall, and shall cause its Subsidiaries to, afford AbbVie, its Subsidiaries and their respective Representatives, upon reasonable advance notice, reasonable access during normal business hours to the facilities, Information, systems, infrastructure, and personnel of Abbott and its Subsidiaries as reasonably necessary for AbbVie to verify the adequacy of internal controls over information technology, reporting of financial data and related processes employed in connection with the Services being provided by Abbott or its Subsidiaries, including in connection with verifying compliance with Section 404 of the Sarbanes-Oxley Act of 2002; provided that (i) such access shall not unreasonably interfere with any of the business or operations of Abbott or any of its Subsidiaries and (ii) in the event that Abbott determines that providing such access could be commercially detrimental, violate any Law or agreement, or waive any attorney-client privilege, then Abbott and AbbVie shall use commercially reasonable efforts to permit such access in a manner that avoids any such harm or consequence.  AbbVie agrees that all of its and its Subsidiaries’ employees shall, and that it shall use commercially reasonable efforts to cause its Representatives’ employees to, when on the property of Abbott and its Subsidiaries, or when

 

10











 

given access to any facilities, Information, systems, infrastructure or personnel of Abbott and its Subsidiaries, conform to the policies and procedures of Abbott and any of its Subsidiaries, as applicable, concerning health, safety, conduct and security which are made known to AbbVie from time to time.

 

ARTICLE IV

 

BILLING; TAXES

 

Section 4.01.                          Procedure.  Charges for the Services shall be charged to and payable by the Recipient.  Amounts payable pursuant to the terms of this Agreement shall be paid by wire transfer (or such other method of payment as may be agreed between the applicable Recipient and Provider) to the Provider, as directed by the Provider, on a monthly basis, which amounts shall be due within sixty (60) days after the date of invoice.  All amounts due and payable hereunder shall be invoiced and paid in the local currency of the Provider.

 

Section 4.02.                          Late Payments.  Charges not paid when due pursuant to this Agreement (and any amounts billed or otherwise invoiced or demanded and properly payable that are not paid within sixty (60) days of the date of such bill, invoice or other demand) shall accrue interest at a rate per annum equal to the Prime Rate plus 2%, or the maximum legal rate, whichever is lower (the “Interest Payment”).

 

Section 4.03.                          Taxes.  Without limiting any provisions of this Agreement, the Recipient shall bear any and all Taxes and other similar charges (and any related interest and penalties) imposed on, or payable with respect to, any fees or charges, including any Charges, payable by it pursuant to this Agreement, including all sales, use, value-added, and similar Taxes, but excluding Taxes based on such Provider’s net income.  Notwithstanding anything to the contrary in the previous sentence or elsewhere in this Agreement, the Recipient shall be entitled to withhold from any payments to the Provider any such Taxes that the Recipient is required by Law to withhold and shall pay such Taxes to the applicable Tax Authority.

 

Section 4.04.                          No Set-Off.  Except as mutually agreed to in writing by Abbott and AbbVie, no Party or any of its Affiliates shall have any right of set off or other similar rights with respect to (a) any amounts received pursuant to this Agreement; or (b) any other amounts claimed to be owed to the other Party or any of its Subsidiaries arising out of this Agreement.

 

ARTICLE V

 

TERM AND TERMINATION

 

Section 5.01.                          Term.  With respect to each Recipient and its applicable Provider of the applicable Services, this Agreement shall commence on the commencement of the applicable Service Period and shall terminate upon the earlier to occur of:  (a) the last date on which such Provider is obligated to provide any Service to such Recipient in accordance with the terms of this Agreement; or (b) the mutual written agreement of Abbott and AbbVie to terminate this Agreement in its entirety.  Unless otherwise terminated pursuant to Section 5.02, this Agreement

 

11











 

shall terminate with respect to any Service for a given Recipient at the close of business on the last day of the Service Period for such Service for such Recipient.

 

Section 5.02.                          Early Termination.

 

(a)                                 Without prejudice to any Recipient’s rights with respect to a Force Majeure, any Recipient may from time to time terminate this Agreement with respect to the entirety of any individual Service but not a portion thereof:

 

(i)                                     for any reason or no reason, upon the giving of an advance Notice to the Provider of such Service not less than the shorter of (A) one hundred eighty (180) days, or (B) one-half the original Service Period for such Service; provided, however, that any such termination may only be effective as of the last day of a month; or

 

(ii)                                  if the Provider of such Service has failed to perform any of its material obligations under this Agreement with respect to such Service, and such failure shall continue to exist forty five (45) days after receipt by such Provider of Notice of such failure from the Recipient; provided, however, that any such termination may only be effective as of the last day of a month; and provided, further, that the Recipient shall not be entitled to terminate the Agreement with respect to the applicable Service if, as of the end of such forty five (45)-day period, there remains a good faith Dispute between such Provider and Recipient (undertaken in accordance with the terms of Section 9.07) as to whether the Provider has cured the applicable breach.

 

(b)                                 Any Provider may terminate this Agreement with respect to any individual Service, but not a portion thereof, at any time upon prior Notice to the applicable Recipient if such Recipient has failed to perform any of its material obligations under this Agreement relating to such Services, including making payment of Charges for such Service when due, and such failure shall continue uncured for a period of forty five (45) days after receipt by such Recipient of a Notice of such failure from the Provider; provided, however, that any such termination may only be effective as of the last day of a month; and provided, further, that the Provider shall not be entitled to terminate this Agreement with respect to the applicable Service if, as of the end of such forty five (45)-day period, there remains a good faith Dispute between such Provider and Recipient (undertaken in accordance with the terms of Section 9.07) as to whether the Recipient has cured the applicable breach.  If a Provider has terminated a Service in accordance with the previous sentence, such Provider shall, without the consent of the Recipient, amend Schedule 1 of the applicable Joinder Agreement to reflect any terminated Service by indicating the early termination date with respect to such terminated Service for such Recipient and shall promptly provide Notice of such amendment (including a copy thereof) to Abbott, AbbVie and the applicable Recipient.

 

Section 5.03.                          Reduction of Services.  Any Recipient may from time to time request a reduction in part of the scope or amount of any Service; provided that any such reduction may only take effect as of the end of a month.  If requested to do so by a Recipient by Notice to Abbott and AbbVie, Abbott and AbbVie shall discuss in good faith appropriate adjustments to the relevant Charges in light of all relevant factors.  If, after such discussions, Abbott and AbbVie do not approve any requested reduction of the scope or amount of any Service and the

 

12











 

relevant Charges in connection therewith, then (a) there shall be no change to the Charges under this Agreement and (b) unless the applicable Recipient and Provider otherwise agree in writing, there shall be no change to the scope or amount of any Services under this Agreement.  If, after such discussions, Abbott and AbbVie approve any reduction of Service, such reduction of Service shall be documented in a written agreement executed on behalf of the applicable Recipient and Provider and such Recipient and Provider shall promptly provide Notice of such agreement (including a copy thereof) to Abbott and AbbVie.  Additionally, in connection with any such reduction of Service, Abbott and AbbVie may approve an appropriate reduction to the Charges related to the applicable reduced Service.

 

Section 5.04.                          Extension of Services.

 

(a)                                 Each Recipient may request to extend the Service Period of any Service (each such extension, a “Service Extension”) one time for each Service unless Abbott and AbbVie shall authorize additional extensions, by providing the Provider of such Service with advance Notice not less than the shorter of (i) one hundred eighty (180) days, or (ii) one-half of the original Service Period for such Service.  Notwithstanding the foregoing, if any Provider and Recipient shall first execute a Joinder Agreement after June 30, 2014, the Service Period for the Services provided by such Provider to such Recipient shall automatically be deemed to terminate on December 31, 2015, unless such Recipient and Provider agree in their applicable Joinder Agreement to a shorter Service Period of any Service to be provided to such Recipient by such Provider, in which case such shorter Service Period shall apply to the particular Service.

 

(b)                                 If the Recipient (other than a Recipient who first executed a Joinder Agreement after June 30, 2014) is requesting a Service Extension for a particular Service for the first time and the requested Service Extension is for a period of twelve (12) months or less past the originally scheduled expiration of the Service Period for the applicable Service, then the Provider shall be obligated to provide such requested Service Extension and the applicable Recipient and Provider shall in good faith (i) negotiate the terms of an amendment to the applicable Joinder Agreement and promptly provide Notice of such amendment (including a copy thereof) to Abbott and AbbVie, which amendment shall be consistent with the terms of the applicable Service, and (ii) determine the costs and expenses (which shall not include any Charges payable under this Agreement), if any, that would be incurred by such Provider or Recipient, as the case may be, in connection with the provision of such Service Extension, which costs and expenses shall be borne solely by the Recipient.  If (A) the requested Service Extension is for a period of longer than twelve (12) months past the originally scheduled expiration of the Service Period for the applicable Service or (B) the applicable Recipient has previously requested a Service Extension for the particular Service that such Recipient is currently requesting a Service Extension, then such Recipient or Provider shall provide Notice of such request to Abbott and AbbVie, and Abbott and AbbVie shall cooperate and act in good faith to determine whether the Provider shall provide the applicable Service for the requested Service Extension period.  If Abbott and AbbVie determine that the Provider shall provide such Service during the requested Service Extension period, then the applicable Recipient and Provider shall in good faith (1) negotiate the terms of an amendment to Schedule 1 of the applicable Joinder Agreement and promptly provide Notice of such amendment (including a copy thereof) to Abbott and AbbVie, which amendment shall be consistent with the terms of the applicable Service, and (2) determine the costs and expenses (which shall not include any Charges payable

 

13











 

under this Agreement), if any, that would be incurred by such Provider or Recipient, as the case may be, in connection with the provision of such Service Extension, which costs and expenses shall be borne solely by the Recipient.

 

(c)                                  Notwithstanding anything in this Agreement to the contrary, that portion of the Service described on Exhibit A-13 (the “Accounting, Reporting & Financial Services”) which relates solely to the applicable Provider’s obligation under this Agreement to collect amounts owed by any Third Party with respect to the AbbVie Business pursuant to a contract between such Third Party, on the one hand, and such Provider alone, on the other hand (such portion of such Service, the “Collection Service”) shall be deemed automatically extended without further action on the part of the applicable Provider or Recipient until the earlier of (i) such date when ninety-five percent (95%) of all amounts owed under all such contracts with respect to the AbbVie Business as of the third (3rd) anniversary of the Effective Time have been collected and (ii) the seventh (7th) anniversary of the Effective Time.

 

Section 5.05.                          Interdependencies.  The Parties acknowledge and agree that (i) there may be interdependencies among the Services being provided under this Agreement, (ii) upon the request of any Provider or Recipient by Notice to Abbott and AbbVie, Abbott and AbbVie shall cooperate and act in good faith to determine whether (A) any such interdependencies exist with respect to the particular Service that such Provider or Recipient is seeking to terminate, reduce part of the scope or amount of, or extend, as applicable, in accordance with Section 5.02, Section 5.03 or Section 5.04, respectively, and (B) in the case of a termination or reduction, the Provider’s ability to provide a particular Service in accordance with this Agreement would be materially and adversely affected by such termination, or reduction in part of the scope or amount, of another Service, as applicable, in accordance with Section 5.02 or Section 5.03, respectively, prior to the expiration of the period of the maximum duration for such Service, and (iii) in the event that Abbott and AbbVie have determined that such interdependencies exist (and, in the case of a termination or reduction, as applicable, that the Provider’s ability to provide a particular Service in accordance with this Agreement would be materially and adversely affected by the termination, or reduction in part of the scope or amount, of another Service, as applicable, in accordance with Section 5.02 or Section 5.03, respectively, prior to the expiration of the period of the maximum duration for such Service), the applicable Provider and Recipient shall negotiate in good faith to amend Schedule 1 of the applicable Joinder Agreement relating to the termination dates of such impacted Services and shall promptly provide Notice of such amendment (including a copy thereof) to Abbott and AbbVie.  Each such amended Joinder Agreement pursuant to this Section 5.02 shall be deemed part of this Agreement as of the date of such amendment.

 

Section 5.06.                          Effect of Termination.  Upon the termination of any Service for any Recipient pursuant to this Agreement, the Provider of the terminated Service shall have no further obligation to provide the terminated Service to such Recipient, and such Recipient shall have no obligation to pay any future Charges relating to any such Service; provided, however, that the Recipient shall remain obligated to the relevant Provider for the Charges owed and payable in respect of Services provided prior to the effective date of termination for such Service.  In connection with the termination of any Service, the provisions of this Agreement not relating solely to such terminated Service shall survive any such termination, and in connection with a termination of this Agreement, Article I, this Article V, Article VII and Article IX, all

 

14











 

confidentiality obligations under this Agreement and Liability for all due and unpaid Charges, shall continue to survive indefinitely.

 

Section 5.07.                          Information Transmission.  Each Provider, on behalf of itself and its respective Subsidiaries, shall use commercially reasonable efforts to provide or make available, or cause to be provided or made available, to its applicable Recipient, in accordance with Section 6.01(a) of the Separation and Distribution Agreement, any Information received or computed by the Provider for the benefit of such Recipient concerning the relevant Service during the Service Period; provided, however, that, except as otherwise agreed to in writing by the Provider and Recipient (a) no Provider shall have any obligation to provide or cause to provide Information in any non-standard format, (b) the Provider and its Subsidiaries shall be reimbursed for their reasonable costs in accordance with Section 6.01(c) of the Separation and Distribution Agreement for creating, gathering, copying, transporting and otherwise providing such Information, and (c) the Provider shall use commercially reasonable efforts to maintain any such Information in accordance with Section 6.03 of the Separation and Distribution Agreement.

 

ARTICLE VI

 

CONFIDENTIALITY; PROTECTIVE ARRANGEMENTS

 

Section 6.01.                          Abbott and AbbVie Obligations.  Subject to Section 6.04, Abbott, on behalf of itself and each of the Abbott Subsidiaries, on the one hand, and AbbVie, on behalf of itself and each of the AbbVie Subsidiaries, on the other hand, agrees to hold, and to cause its respective Representatives to hold, in strict confidence, with at least the same degree of care that applies to Abbott’s confidential and proprietary information pursuant to policies in effect as of the Effective Time, all confidential and proprietary information concerning the other Party (or its business) and the other Party’s Subsidiaries (or their respective businesses) that is either in its possession (including confidential and proprietary information in its possession prior to the Effective Time) or furnished by such other Party or such other Party’s Subsidiaries or their respective Representatives at any time pursuant to this Agreement, and shall not use any such confidential and proprietary information other than for such purposes as may be expressly permitted hereunder, except, in each case, to the extent that such confidential and proprietary information has been (a) in the public domain or generally available to the public, other than as a result of a disclosure by such Party or any of its Subsidiaries or any of their respective Representatives in violation of this Agreement; (b) later lawfully acquired from other sources by such Party or any of its Subsidiaries, which sources are not themselves bound by a confidentiality obligation or other contractual, legal or fiduciary obligation of confidentiality with respect to such confidential and proprietary information; or (c) independently developed or generated without reference to or use of the respective proprietary or confidential information of such other Party or any of its Subsidiaries.  If any confidential and proprietary information of Abbott or any of its Subsidiaries is disclosed to AbbVie or any of its Subsidiaries in connection with providing the Services, then such disclosed confidential and proprietary information shall be used only as required to perform the Services.  If any confidential and proprietary information of AbbVie or any of its Subsidiaries is disclosed to Abbott or any of its Subsidiaries in connection with providing the Services, then such disclosed confidential and proprietary information shall be used only as required to perform such Services.

 

15









 

Section 6.02.                          No Release.  Each Party agrees (a) not to release or disclose, or permit to be released or disclosed, any information addressed in Section 6.01 to any other Person, except its Representatives who need to know such information in their capacities as such, and except in compliance with Section 6.04, and (b) to use commercially reasonable efforts to maintain any such information in accordance with Section 6.03 of the Separation and Distribution Agreement.

 

Section 6.03.                          Third Party Information; Privacy and Data Protection Laws.  Each Party acknowledges that it and its respective Subsidiaries may presently have and, following the Effective Time, may gain access to or possession of confidential or proprietary information of, or personal information relating to, Third Parties (a) that was received under confidentiality or non-disclosure agreements entered into between such Third Parties, on the one hand, and the other Party or the other Party’s Subsidiaries, on the other hand, prior to the Effective Time; or (b) that, as between the Parties, was originally collected by the other Party or the other Party’s Subsidiaries and that may be subject to and protected by privacy, data protection or other applicable Laws.  As provided in more detail in a data protection agreement to be entered into between Abbott and AbbVie as of the Effective Time, each of Abbott and AbbVie agrees that it shall hold, protect and use, and shall cause its Subsidiaries and its and its Subsidiaries’ respective Representatives to hold, protect and use, in strict confidence the confidential and proprietary information of, or personal information relating to, Third Parties in accordance with privacy, data protection or other applicable Laws and the terms of any agreements that were either entered into before the Effective Time or affirmative commitments or representations that were made before the Effective Time by, between or among such other Party or such other Party’s Subsidiaries, on the one hand, and such Third Parties, on the other hand.

 

Section 6.04.                          Protective Arrangements.  In the event that any Party or any of its Affiliates is requested or required (by oral question, interrogatories, requests for information or documents, subpoena, civil investigative demand or similar process) by any Governmental Authority or pursuant to applicable Law to disclose or provide any confidential or proprietary information of the other Party that is subject to the confidentiality provisions hereof, or to disclose or provide any Personal Data that it processes on behalf of the other Party in accordance with the data protection agreement to be entered into between Abbott and AbbVie as of the Effective Time, such Party shall, unless prohibited by such request or requirement of the applicable Governmental Authority or under applicable Law, provide such other Party with Notice of such request or demand as promptly as practicable under the circumstances so that such other Party shall have an opportunity to seek an appropriate protective order, at such other Party’s own cost and expense.  In the event that such other Party fails to receive such appropriate protective order in a timely manner and the Party receiving the request or demand reasonably determines that its failure to disclose or provide such information shall actually prejudice the Party receiving the request or demand, then the Party that received such request or demand may thereafter disclose or provide information to the extent required by such Law (as so advised by counsel) or by lawful process or such Governmental Authority.

 

16











 

ARTICLE VII

 

LIMITED LIABILITY AND INDEMNIFICATION

 

Section 7.01.                          Limitations on Liability.

 

(a)                                 SUBJECT TO SECTION 7.02, THE LIABILITIES OF EACH PROVIDER AND ITS SUBSIDIARIES AND THEIR RESPECTIVE REPRESENTATIVES, COLLECTIVELY, UNDER THIS AGREEMENT FOR ANY ACT OR FAILURE TO ACT IN CONNECTION HEREWITH (INCLUDING THE PERFORMANCE OR BREACH OF THIS AGREEMENT), OR FROM THE SALE, DELIVERY, PROVISION OR USE OF ANY SERVICES PROVIDED UNDER OR CONTEMPLATED BY THIS AGREEMENT, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT LIABILITY) OR OTHERWISE, SHALL NOT EXCEED SUCH PROVIDER’S PROFITS FOR PERFORMING SERVICES HEREUNDER, WHICH SHALL BE DEEMED TO BE EQUAL TO THE AMOUNT OF THE MARK-UP RECEIVED BY SUCH PROVIDER DURING THE PREVIOUS TWELVE (12) MONTH PERIOD.

 

(b)                                 IN NO EVENT SHALL ANY PARTY, ITS SUBSIDIARIES OR THEIR RESPECTIVE REPRESENTATIVES BE LIABLE TO ANY OTHER PARTY FOR INDIRECT, EXEMPLARY, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THE PERFORMANCE OF THIS AGREEMENT, EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND EACH PARTY HEREBY WAIVES ON BEHALF OF ITSELF, ITS SUBSIDIARIES AND ITS REPRESENTATIVES ANY CLAIM FOR SUCH DAMAGES, INCLUDING ANY CLAIM FOR PROPERTY DAMAGE OR LOST PROFITS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE.

 

(c)                                  The foregoing limitations on Liability in this Section 7.01 shall not apply to any Party’s Liability for breaches of confidentiality under Article VI or any Party’s obligations under Section 7.03.

 

(d)                                 The limitations in Section 7.01(a) and Section 7.01(b) shall not apply in respect of any Liability arising out of or in connection with the gross negligence, willful misconduct, or fraud of or by the Party to be charged.

 

Section 7.02.                          Obligation to Re-Perform; Liabilities.  In the event of any breach of this Agreement by any Provider with respect to the provision of any Services (with respect to which the Provider can reasonably be expected to re-perform in a commercially reasonable manner), such Provider shall (a) promptly correct in all material respects such error, defect or breach or re-perform in all material respects such Services at the request of its applicable Recipient and at the sole cost and expense of the Provider and (b) subject to the limitations set forth in Section 7.01, reimburse such Recipient and its Subsidiaries and Representatives for Liabilities attributable to such breach by such Provider.  The remedy set forth in this Section 7.02 shall be the sole and exclusive remedy of the Recipient for any such breach of this Agreement.  Any request for re-performance in accordance with this Section 7.02 by any Recipient must be in writing and specify in reasonable detail the particular error, defect or breach, and such request must be made

 

17











 

no more than one (1) month from the later of the date on which such breach occurred and the date on which such breach was reasonably discovered by the Recipient.

 

Section 7.03.                          Third Party Claims.  Each Recipient shall indemnify, defend and hold harmless its applicable Provider, its Subsidiaries and each of their respective Representatives, and each of the successors and assigns of any of the foregoing (collectively, the “Provider Indemnitees”), from and against any and all claims of Third Parties relating to, arising out of or resulting from such Provider’s furnishing or failing to furnish the Services provided for in this Agreement, other than (a) Third Party claims arising out of the gross negligence, willful misconduct or fraud of any Provider Indemnitee and (b) as set forth in Section 2.03(b).

 

Section 7.04.                          Indemnification Procedures.  The provisions of Article IV of the Separation and Distribution Agreement shall govern claims for indemnification under this Agreement; provided that, for purposes of this Section 7.04, in the event of any conflict between the provisions of Article IV of the Separation and Distribution Agreement and this Article VII, the provisions of this Agreement shall control.

 

ARTICLE VIII

 

TRANSITION COMMITTEE; ABBOTT AND ABBVIE RIGHTS

 

Section 8.01.                          Establishment.  Pursuant to the Separation and Distribution Agreement, a Transition Committee is to be established by Abbott and AbbVie to, among other things, monitor and manage matters arising out of or resulting from this Agreement.

 

Section 8.02.                          Rights of Abbott and AbbVie.  Notwithstanding any provision in this Agreement to the contrary, each Provider and Recipient acknowledges and agrees that Abbott and AbbVie shall have the right to review and amend any prior actions taken, decisions made or amendments or modifications agreed to, by each Provider and Recipient, and jointly to proscribe that any Provider and applicable Recipient take such actions or make such amendments or modifications as Abbott and AbbVie deem appropriate in order to effect the intent and purpose of this Agreement and the transactions contemplated hereby.  Each Provider and Recipient shall take, or cause to be taken, any and all reasonable actions that Abbott and AbbVie jointly may reasonably request to carry out the intent and purpose of this Article VIII.

 

ARTICLE IX

 

MISCELLANEOUS

 

Section 9.01.                          Mutual Cooperation.  The Parties and their respective Subsidiaries shall cooperate with each other in connection with the performance of the Services hereunder; provided, however, that such cooperation shall not unreasonably disrupt the normal operations of the Parties and their respective Subsidiaries; and, provided, further, that this Section 9.01 shall not require any Party to incur any out-of-pocket costs or expenses unless and except as expressly provided in this Agreement or otherwise agreed to in writing by Abbott and AbbVie.

 

Section 9.02.                          Title to Intellectual Property.  Except as expressly provided for under the terms of this Agreement, each Recipient acknowledges that it shall acquire no right, title or

 

18











 

interest (including any license rights or rights of use) in any intellectual property which is owned or licensed by any Provider, by reason of the provision of the Services provided hereunder.  No Recipient shall remove or alter any copyright, trademark, confidentiality or other proprietary notices that appear on any intellectual property owned or licensed by any Provider, and each Recipient shall reproduce any such notices on any and all copies thereof.  No Recipient shall attempt to decompile, translate, reverse engineer or make excessive copies of any intellectual property owned or licensed by any Provider, and each Recipient shall promptly notify such Provider of any such attempt, regardless of whether by the Recipient or any Third Party, of which the Recipient becomes aware.

 

Section 9.03.                          Force Majeure.  No Party shall be deemed in default of this Agreement for failure to fulfill any obligation so long as and to the extent to which any delay or failure in the fulfillment of such obligations is prevented, frustrated, hindered or delayed as a consequence of circumstances of Force Majeure.  In the event of any such excused delay, the time for performance shall be extended for a period equal to the time lost by reason of the delay unless this Agreement has previously been terminated under Article V or under this Section 9.03.  Any Party claiming the benefit of this provision shall, as soon as reasonably practicable after the occurrence of any such event, (a) provide Notice to the other Party of the nature and extent of any such Force Majeure condition; and (b) use commercially reasonable efforts to remove any such causes and resume performance under this Agreement as soon as reasonably practicable unless this Agreement has previously been terminated under Article V or under this Section 9.03.  During the period of a Force Majeure, the applicable Recipient shall be (i) relieved of the obligation to pay Charges for such Service(s) throughout the duration of such Force Majeure and (ii) entitled to permanently terminate such Service(s) (and shall be relieved of the obligation to pay Charges for such Service(s) throughout the duration of such Force Majeure) if a Force Majeure shall continue to exist for more than thirty (30) consecutive days, it being understood that such Recipient shall not be required to provide any advance notice of such termination to the Provider.

 

Section 9.04.                          Independent Contractors.  The Parties each acknowledge that they are separate entities, each of which has entered into this Agreement for independent business reasons.  The relationships of the Parties hereunder are those of independent contractors and nothing contained herein shall be deemed to create a joint venture, partnership or any other relationship.  Employees performing services hereunder do so on behalf of, under the direction of, and as employees of, the applicable Provider, and the applicable Recipient shall have no right, power or authority to direct such employees.

 

Section 9.05.                          Third Party Beneficiaries.  Except as provided in Article VII with respect to Provider Indemnitees, (a) the provisions of this Agreement are solely for the benefit of the Parties, their Subsidiaries and their permitted successors and assigns, and are not intended to confer upon any other Person except the Parties, their Subsidiaries and their permitted successors and assigns, any rights or remedies hereunder; and (b) there are no other Third Party beneficiaries of this Agreement and this Agreement shall not provide any other Third Party with any remedy, claim, Liability, reimbursement, claim of action or other right in excess of those existing without reference to this Agreement.

 

19











 

Section 9.06.                          Governing Law.  This Agreement shall be governed by and construed and interpreted in accordance with the Laws of the State of Delaware, irrespective of the choice of Laws principles of the State of Delaware, as to all matters, including matters of validity, construction, effect, enforceability, performance and remedies.

 

Section 9.07.                          Dispute Resolution.

 

(a)                                 In the event of any controversy, dispute or claim (a “Dispute”) arising out of or relating to any Party’s rights or obligations under this Agreement (whether arising in contract, tort or otherwise) or calculation or allocation of the costs of any Service, or otherwise arising out of or relating in any way to this Agreement (including the interpretation or validity of this Agreement), such Dispute shall be resolved in accordance with the dispute resolution process referred to in Section 7.01 to the Separation and Distribution Agreement.

 

(b)                                 In any Dispute regarding the amount of a Charge, if such Dispute is finally resolved pursuant to the dispute resolution process set forth or referred to in Section 9.07(a) and it is determined that the Charge that the Provider has invoiced the Recipient, and that the Recipient has paid to the Provider, is greater or less than the amount that the Charge should have been, then (i) if it is determined that the Recipient has overpaid the Charge, the Provider shall within five (5) business days after such determination reimburse the Recipient an amount of cash equal to such overpayment, plus the Interest Payment, accruing from the date of payment by the Recipient to the time of reimbursement by the Provider; and (ii) if it is determined that the Recipient has underpaid the Charge, the Recipient shall within five (5) business days after such determination reimburse the Provider an amount of cash equal to such underpayment, plus the Interest Payment, accruing from the date such payment originally should have been made by the Recipient to the time of payment by the Recipient.

 

Section 9.08.                          Specific Performance.  Subject to Section 9.07, in the event of any actual or threatened default in, or breach of, any of the terms, conditions and provisions of this Agreement, the Party or Parties who are or are to be thereby aggrieved shall have the right to specific performance and injunctive or other equitable relief (on an interim or permanent basis) of its rights under this Agreement, in addition to any and all other rights and remedies at Law or in equity, and all such rights and remedies shall be cumulative.  The Parties agree that the remedies at Law for any breach or threatened breach, including monetary damages, may be inadequate compensation for any loss and that any defense in any Proceeding for specific performance that a remedy at Law would be adequate is waived.  Unless otherwise agreed in writing, the Parties shall continue to provide Services and honor all other commitments under this Agreement during the course of dispute resolution pursuant to the provisions of Section 9.07 and this Section 9.08 with respect to all matters subject to such Dispute; provided, however, that this obligation shall only exist during the term of this Agreement.

 

Section 9.09.                          Interpretation.  Words in the singular shall be deemed to include the plural and vice versa and words of one gender shall be deemed to include the other genders as the context requires.  The terms “hereof,” “herein,” and “herewith” and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole (including all of the Schedules and Exhibits hereto and thereto) and not to any particular provision of this Agreement.  Section, Exhibit and Schedule references are to the Sections, Exhibits, and

 

20











 

Schedules to this Agreement unless otherwise specified.  Unless otherwise stated, all references to any agreement shall be deemed to include the exhibits, schedules and annexes to such agreement.  The word “including” and words of similar import when used in this Agreement shall mean “including, without limitation,” unless the context otherwise requires or unless otherwise specified.  The word “or” shall not be exclusive.  Unless otherwise specified in a particular case, the word “days” refers to calendar days.  References herein to this Agreement or any other agreement contemplated herein shall be deemed to refer to this Agreement or such other agreement as of the date on which it is executed and as it may be amended, modified or supplemented thereafter, unless otherwise specified.  References to the performance, discharge or fulfillment of any Liability in accordance with its terms shall have meaning only to the extent such Liability has terms.  If the Liability does not have terms, the reference shall mean performance, discharge or fulfillment of such Liability.

 

Section 9.10.                          Headings.  The Article, Section and Paragraph headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

 

Section 9.11.                          Amendment.  Except with respect to the execution of any Joinder Agreement, or the amendment, supplementation or modification thereof in accordance with the terms and provisions of such Joinder Agreement, no provisions of this Agreement shall be deemed amended, supplemented or modified unless such amendment, supplement or modification is in writing and signed by an authorized representative of each of Abbott and AbbVie.  No provisions of this Agreement shall be deemed waived unless such waiver is in writing and signed by the authorized representative of the Party against whom it is sought to be enforced.

 

Section 9.12.                          Assignability.  This Agreement shall not be assigned without the prior written consent of Abbott and AbbVie, except that:

 

(a)                                 each Party may assign all of its rights and obligations under this Agreement to any of its Subsidiaries; provided, however, that no such assignment shall release the assigning Party from any Liability under this Agreement; and

 

(b)                                 in connection with (i) the divestiture of all or substantially all of the assets of a Recipient or Provider to a Third Party or (ii) a Change of Control of a Recipient or Provider, the applicable Recipient or Provider may assign to such Third Party its rights and obligations as a Recipient or Provider under this Agreement; provided, however, that (x) no such assignment shall release the assigning Party from any Liability under this Agreement, (y) any and all costs and expenses incurred by any Party in connection with such assignment (including in connection with clause (z) of this proviso) shall be borne solely by the assigning Party, and (z) Abbott and AbbVie shall in good faith negotiate any amendments to this Agreement, including the Exhibits and Schedules to this Agreement, that may be reasonably necessary in order to assign such Services.

 

Section 9.13.                          Audit Assistance.  Each of the Parties and their respective Subsidiaries are or may be subject to regulation and audit by a Governmental Authority, standards organizations, customers or other parties to contracts with such Parties or their respective Subsidiaries under

 

21











 

applicable Law, standards or contract provisions.  If a Governmental Authority, standards organization, customer or other party to a contract with a Party or its Subsidiary exercises its right to examine or audit such Party’s or its Subsidiary’s books, records, documents or accounting practices and procedures pursuant to such applicable Law, standards or contract provisions, and such examination or audit relates to the Services, then the other Parties shall provide, at the sole cost and expense of the requesting Party, all assistance reasonably requested by the Party that is subject to the examination or audit in responding to such examination or audits or requests for information, to the extent that such assistance or information is within the reasonable control of the cooperating Party and is related to the Services.

 

Section 9.14.                          Survival of Covenants.  Except as expressly set forth in this Agreement, the covenants and other agreements contained in this Agreement, and Liability for the breach of any obligations contained herein, shall survive the Effective Time and shall remain in full force and effect thereafter.

 

Section 9.15.                          Subsidiaries.  Abbott shall cause to be performed, and hereby guarantees the performance of, all actions, agreements and obligations set forth herein and in any Joinder Agreement to be performed by an Abbott Subsidiary and AbbVie shall cause to be performed, and hereby guarantees the performance of, all actions, agreements and obligations set forth herein and in any Joinder Agreement to be performed by an AbbVie Subsidiary.

 

Section 9.16.                          Waivers of Default.  Waiver by any Party of any default by the other Party of any provision of this Agreement shall not be deemed a waiver by the waiving Party of any subsequent or other default, nor shall it prejudice the rights of the waiving Party.

 

Section 9.17.                          Notices.  All Notices under this Agreement shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by overnight courier service, by facsimile with receipt confirmed (followed by delivery of an original via overnight courier service) or by registered or certified mail (postage prepaid, return receipt requested) to the respective Parties at the following addresses, with a copy (which shall not constitute Notice) to the applicable Abbott Subsidiary or applicable AbbVie Subsidiary at the respective addresses set forth in the applicable Joinder Agreement (or at such other address for a Party as shall be specified in a Notice):

 

If to Abbott:

 

Abbott Laboratories
 100 Abbott Park Road
 Abbott Park, Illinois 60064-6020
 Attn: Divisional Vice President, Abbott Transition Organization

Facsimile: (847) 938-5313

 

22











 

If to AbbVie:

 

AbbVie Inc. 
 1 North Waukegan Road
 North Chicago, Illinois 60064
 Attn: Vice President, Strategic Initiative

Facsimile: (847) 937-4330

 

Abbott and AbbVie may, by Notice to such other Party, change the address to which such Notices are to be given.

 

Section 9.18.                          Counterparts.  This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement.

 

Section 9.19.                          Entire Agreement.  This Agreement, the Joinder Agreements, and the exhibits and schedules hereto and thereto contain the entire agreement between the Parties with respect to the subject matter hereof, supersede all previous agreements, negotiations, discussions, writings, understandings, commitments and conversations with respect to such subject matter and there are no agreements or understandings between the Parties other than those set forth or referred to herein or therein.

 

Section 9.20.                          Corporate Power.  Abbott represents on behalf of itself and, to the extent applicable, each Abbott Subsidiary, and AbbVie represents on behalf of itself and, to the extent applicable, each AbbVie Subsidiary, as follows:

 

(a)                                 each such Person has the requisite corporate or other power and authority and has taken all corporate or other action necessary in order to execute, deliver and perform this Agreement and to consummate the transactions contemplated hereby; and

 

(b)                                 this Agreement has been duly executed and delivered by it and constitutes a valid and binding agreement of it enforceable in accordance with the terms hereof.

 

Section 9.21.                          Signatures and Delivery.  Each of Abbott and AbbVie acknowledges that it may execute this Agreement by manual, stamp or mechanical signature, and that delivery of an executed counterpart of a signature page to this Agreement (whether executed by manual, stamp or mechanical signature) by facsimile or by email in portable document format (PDF) shall be effective as delivery of such executed counterpart of this Agreement.  Each of Abbott and AbbVie expressly adopts and confirms a stamp or mechanical signature (regardless of whether delivered in person, by mail, by courier, by facsimile or by email in portable document format (PDF)) made in its respective name as if it were a manual signature delivered in person, agrees that it shall not assert that any such signature or delivery is not adequate to bind it to the same extent as if it were signed manually and delivered in person and agrees that, at the reasonable request of the other Party at any time, it shall as promptly as reasonably practicable cause this Agreement to be manually executed (any such execution to be as of the date of the initial date hereof) and delivered in person, by mail or by courier.

 

Section 9.22.                          Severability.  In the event that any one or more of the terms or provisions of this Agreement or the application thereof to any Person or circumstance is determined by a

 

23











 

court of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement, or the application of such term or provision to Persons or circumstances or in jurisdictions other than those as to which it has been determined to be invalid, illegal or unenforceable, and Abbott and AbbVie shall use their commercially reasonable efforts to substitute one or more valid, legal and enforceable terms or provisions into this Agreement which, insofar as practicable, implement the purposes and intent of the Parties.  Any term or provision of this Agreement held invalid or unenforceable only in part, degree or within certain jurisdictions shall remain in full force and effect to the extent not held invalid or unenforceable to the extent consistent with the intent of the Parties as reflected by this Agreement.  To the extent permitted by applicable Law, each Party waives any term or provision of Law which renders any term or provision of this Agreement to be invalid, illegal or unenforceable in any respect.

 

Section 9.23.                          Attorney-in-Fact.  Each Abbott Subsidiary that executes a Joinder Agreement designates and appoints Abbott as such Party’s agent and attorney-in-fact with full power and authority to act for and on behalf of such Party in the absolute discretion of Abbott, and each AbbVie Subsidiary that executes a Joinder Agreement designates and appoints AbbVie as such Party’s agent and attorney-in-fact with full power and authority to act for and on behalf of such Party in the absolute discretion of AbbVie, in each case with respect to all matters relating to this Agreement, including execution and delivery of any amendment, supplement, modification or termination of this Agreement and any waiver of any claim or right arising out of this Agreement, agreeing on the Charges from time to time and any adjustments thereto, and, in general, to do all things and to perform all acts, including executing and delivering all agreements, certificates, receipts, instructions, and other instruments contemplated by or deemed advisable to effectuate the provisions of this Section 9.23.  In addition, the Parties agree that:

 

(a)                                 This appointment and grant of power and authority is coupled with an interest and is in consideration of the mutual covenants made in this Agreement and is irrevocable and will not be terminated by any act of any Abbott Subsidiary or AbbVie Subsidiary that is a Party or by operation of Law or by the occurrence of any other event.  Each Abbott Subsidiary that is a Party hereby consents to the taking of any and all actions and the making of all decisions required or permitted to be taken or made by Abbott pursuant to this Section 9.23, and each AbbVie Subsidiary that is a Party hereby consents to the taking of any and all actions and the making of all decisions required or permitted to be taken or made by AbbVie pursuant to this Section 9.23.  Each Abbott Subsidiary that is a Party agrees that Abbott shall have no obligation or Liability to any Person for any action taken or omitted by Abbott in good faith, and each AbbVie Subsidiary that is a Party agrees that AbbVie shall have no obligation or Liability to any Person for any action taken or omitted by AbbVie in good faith; and

 

(b)                                 Abbott shall be entitled to rely upon any document or other paper delivered by AbbVie as being authorized by each AbbVie Subsidiary that is a Party, and AbbVie shall be entitled to rely upon any document or other paper delivered by Abbott as being authorized by each Abbott Subsidiary that is a Party.

 

Section 9.24.                          Further Assurances.  Each Party hereto shall take, or cause to be taken, any and all reasonable actions, including the execution, acknowledgment, filing and delivery of

 

24











 

any and all documents and instruments that any other Party hereto may reasonably request in order to effect the intent and purpose of this Agreement and the transactions contemplated hereby.

 

Section 9.25.                          Public Announcements.  From and after the Effective Time, Abbott and AbbVie shall consult with each other before issuing, and give each other the opportunity to review and comment upon, that portion of any press release or other public statements that relates to the transactions contemplated by this Agreement, and shall not issue any such press release or make any such public statement prior to such consultation, except as may be required by applicable Law, court process or by obligations pursuant to any listing agreement with any national securities exchange or national securities quotation system.  No other Provider or Recipient shall issue any press release or other public statement with respect to the transactions contemplated by this Agreement without the prior written consent of Abbott and AbbVie.

 

Section 9.26.                          Mutual Drafting.  This Agreement shall be deemed to be the joint work product of the Parties and any rule of construction that a document shall be interpreted or construed against a drafter of such document shall not be applicable.

 

* * * * *

 

25









 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives.

 

 

	
ABBOTT LABORATORIES
    	
 
    	
ABBVIE   INC.
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
By:
    	
/s/   Thomas C. Freyman
    	
 
    	
By:
    	
/s/   Richard A. Gonzalez
    
	
 
    	
Name:
    	
Thomas   C. Freyman
    	
 
    	
 
    	
Name:
    	
Richard   A. Gonzalez
    
	
 
    	
Title:
    	
Executive   Vice President, Finance and Chief Financial Officer
    	
 
    	
 
    	
Title:
    	
Chairman   of the Board and Chief Executive Officer
    


 

[Signature Page to Ex-U.S. Transition Services Agreement]

 











 

Exhibit A-1 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Other Manufacturing Costs
    
	
Description of TSA Services:
    	
 
    	
Provide other manufacturing services required to   support the business of the Service Recipient.

 

Services may include, but are not limited to:   labeling, stickering, inventory re-work and similar ancillary activities, as   historically provided within or among Abbott Divisions. Services do not   include core product manufacturing.
    


 

A-1











 

Exhibit A-2 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Quality Assurance
    
	
Description of TSA Services:
    	
 
    	
Provide quality assurance services required to   support the business of the Service Recipient.

 

Services may include, but are not limited to:   quality management, validation, complaints and product actions, and   documentation & change control, as historically provided within or among   Abbott Divisions.
    


 

A-2











 

Exhibit A-3 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Distribution — Order Entry
    
	
Description of TSA Services:
    	
 
    	
Provide distribution — order entry services   required to support the business of the Service Recipient.

 

Services may include, but are not limited to:   customer order-taking, administration & review of customer orders, issue   resolution and related functions, as historically provided within or among   Abbott Divisions.
    


 

A-3











 

Exhibit A-4 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Distribution — Warehousing
    
	
Description of TSA Services:
    	
 
    	
Provide distribution — warehousing services   required to support the business of the Service Recipient.

 

Services may include, but are not limited to:   receipt, storage, order picking and dispatch of products and related   services, as historically provided within or among Abbott Divisions.
    


 

A-4











 

Exhibit A-5 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Other Charges to COGS
    
	
Description of TSA Services:
    	
 
    	
Provide other charges to COGS services required to   support the business of the Service Recipient.  

 

Services may include, but are not limited to:   ancillary distribution or logistics support services historically provided   within or among Abbott Divisions and not included as part of the order entry   or warehouse / logistics service categories.
    


 

A-5











 

Exhibit A-6 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Regulatory Affairs
    
	
Description of TSA Services:
    	
 
    	
Provide regulatory affairs services required to   support the business of the Service Recipient.  

 

Services may include, but are not limited to:   promotional review, clinical study support, preparation & review of   regulatory documentation, interface with key regulatory agencies and   resolution of regulatory issues, as historically provided within or among   Abbott Divisions.
    


 

A-6











 

Exhibit A-7 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Medical Affairs
    
	
Description of TSA Services:
    	
 
    	
Provide medical affairs services required to   support the business of the Service Recipient.

 

Services may include, but are not limited to:   safety data analysis and collection for marketed and investigational   products, review of promotional literature and interaction with physicians   who may require particular information that cannot be provided by the   commercial team, as historically provided within or among Abbott Divisions.
    


 

A-7











 

Exhibit A-8 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Pharmacovigilance
    
	
Description of TSA Services:
    	
 
    	
Provide medical affairs services required to   support the business of the Service Recipient.

 

Services may include, but are not limited to:   adverse event data collection reporting and analysis and support of active   surveillance and observational study activities, as historically provided within or among Abbott Divisions.
    


 

A-8











 

Exhibit A-9 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Development
    
	
Description of TSA Services:
    	
 
    	
Provide development services required to support   the business of the Service Recipient.

 

Services may include, but are not limited to:   management of clinical trials, operations management for the planning,   execution and reporting of clinical development, and support to enable   commercialization of drug development projects, as historically provided   within or among Abbott Divisions.
    


 

A-9









 

Exhibit A-10 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Other R&D / Medical
    
	
Description of TSA Services:
    	
 
    	
Provide other R&D/medical services required to   support the business of the Service Recipient.

 

Services may include, but are not limited to:   ancillary R&D/medical support services as historically provided within or   among Abbott Divisions and not included as part of the regulatory affairs,   medical affairs, pharmacovigilance or development service categories.
    


 

A-10











 

Exhibit A-11 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Advertising / Marketing
    
	
Description of TSA Services:
    	
 
    	
Provide advertising / marketing services required   to support the business of the Service Recipient.

 

Services may include, but are not limited to: ancillary   advertising / marketing support services, as historically provided within or   among Abbott Divisions.
    


 

A-11











 

Exhibit A-12 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Sales Force Support
    
	
Description of TSA Services:
    	
 
    	
Provide sales force support services required to   support the business of the Service Recipient.

 

Services may include, but are not limited to:   ancillary sales force support services, as historically provided within or   among Abbott Divisions.
    


 

A-12











 

Exhibit A-13 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Accounting, Reporting & Financial Services
    
	
Description of TSA Services:
    	
 
    	
Provide accounting, reporting and financial   services required to support the business of the Service Recipient. Services   will be provided in accordance with U.S. Generally Accepted Accounting   Principles (reported monthly), local statutory requirements (reported   annually or as frequently as required by this jurisdiction), and current   Abbott Financial policies and procedures. Any financial calculations will be   done using established Abbott methods.

 

Services will be provided using Abbott’s existing   systems and processes and may include, but are not limited to: general   accounting & reporting, accounts receivable, inventory accounting, fixed   asset accounting, accounts payable, travel expense processing and reporting,   payroll, treasury and similar services, as historically provided within or   among Abbott Divisions.
    


 

A-13











 

Exhibit A-14 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Financial Planning & Analysis
    
	
Description of TSA Services:
    	
 
    	
Provide financial planning & analysis services   required to support the business of the Service Recipient.

 

Services may include, but are not limited to: data   aggregation, analysis and reporting services, as historically provided within   or among Abbott Divisions.
    


 

A-14











 

Exhibit A-15 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Information Technology
    
	
Description of TSA Services:
    	
 
    	
Provide information technology services required   to support the business of the Service Recipient.  

 

Services may include, but are not limited to:   application support, infrastructure support, desktop support and other IT   support services.  IT systems supported   may include, but are not limited to: enterprise systems (email, Sharepoint, etc.),   transaction systems (BPCS, SAP, etc.) and ancillary support systems (Data   analytics, CRM solutions, etc.), as historically provided within or among   Abbott Divisions.
    


 

A-15











 

Exhibit A-16 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Office Space, Facilities & Related
    
	
Description of TSA Services:
    	
 
    	
Provide office space, facilities & related   services required to support the business of the Service Recipient.

 

Services may include, but are not limited to:   reception, security, mail, utilities and similar services, as historically   provided within or among Abbott Divisions. Services do not include lease or sublease   of facilities where those services are addressed in a separate lease or   sublease agreement.
    


 

A-16











 

Exhibit A-17 — Ex-US TSA Service

 

	
TSA Title:
    	
 
    	
Other General Administration
    
	
Description of TSA Services:
    	
 
    	
Provide other general administration services   required to support the business of the Service Recipient.

 

Services may include, but are not limited to:   ancillary general administration support services historically provided   within or among Abbott Divisions and not included as part of the accounting   reporting & financials services, financial planning & analysis, or   information technology service categories.
    


 

A-17











 

Exhibit B

 

Omitted Services/Additional Services Template

 

	
TSA Title:
    	
 
    	
 
    
	
Description of TSA Services:
    	
 
    	
 
    


 

B-1









 

Exhibit C

 

Joinder Agreement

 

C-1









 

THIS JOINDER AGREEMENT (“Joinder Agreement”) is executed pursuant to Section 2.09 of the Ex-U.S. Transition Services Agreement dated as of December 31, 2012 (the “Ex-U.S. TSA”), and is dated as of [·], 2012, by and between [name of Abbott Subsidiary], a [entity type] organized under the laws of [Jurisdiction] (“Abbott Subsidiary”) and [name of AbbVie Subsidiary], a [entity type] organized under the laws of [Jurisdiction] (“AbbVie Subsidiary”), as a Provider or Recipient, as applicable, as indicated on Schedule 1 hereto.  Terms used herein and not otherwise defined herein shall have the meanings attributed to them in the Ex-U.S. TSA.

 

R E C I T A L S:

 

WHEREAS, the board of directors of Abbott Laboratories, an Illinois corporation (“Abbott”), has determined that it is appropriate and advisable to separate Abbott’s research-based pharmaceuticals business from its other businesses;

 

WHEREAS, in order to effectuate the foregoing, Abbott and AbbVie Inc., a Delaware corporation (“AbbVie”), have entered into a Separation and Distribution Agreement, dated as of November 28, 2012 (the “Separation and Distribution Agreement”), which provides for, among other things, the contribution from Abbott to AbbVie of certain assets, the assumption by AbbVie of certain Liabilities (as defined in the Separation and Distribution Agreement) from Abbott, the distribution by Abbott of AbbVie common stock to Abbott shareholders, and the execution and delivery of certain agreements in order to facilitate and provide for the foregoing, in each case subject to the terms and conditions set forth therein;

 

WHEREAS, in order to facilitate and provide for an orderly transition under the Separation and Distribution Agreement, Abbott and AbbVie have entered into the Ex-U.S. TSA, which sets forth the terms and conditions pursuant to which each Provider shall provide to the applicable Recipient the Services described in the Ex-U.S. TSA for a transitional period; and

 

WHEREAS, each of Abbott Subsidiary and AbbVie Subsidiary desire to execute this Joinder Agreement to be bound by the terms of the Ex-U.S. TSA.

 

NOW, THEREFORE, in consideration of the mutual agreements, provisions and covenants contained in this Joinder Agreement and the Ex-U.S. TSA, Abbott Subsidiary and AbbVie Subsidiary hereby agree as follows:

 

1.                                      Agreement to be Bound.  Each of Abbott Subsidiary and AbbVie Subsidiary agree that, with effect from the Commencement Date set forth in Schedule 1 hereto and pursuant to Section 2.09 of the Ex-U.S. TSA, it shall become a party to the Ex-U.S. TSA as a Provider and a Recipient, respectively, and shall be fully bound by and subject to all of the covenants, terms and conditions of the Ex-U.S. TSA with the same force and effect as if it were an original party thereto.  Each of Abbott Subsidiary and AbbVie Subsidiary acknowledges that it has received a copy of the Ex-U.S. TSA.

 











 

2.                                      Corporate Power.  Each party to this Joinder Agreement represents as follows:

 

(a)                                 it has the requisite corporate or other power and authority and has taken all corporate or other action necessary in order to execute, deliver and perform this Joinder Agreement and the Ex-U.S. TSA and to consummate the transactions contemplated hereby and thereby; and

 

(b)                                 this Joinder Agreement has been duly executed and delivered by it and, together with the Ex-U.S. TSA, constitutes a valid and binding agreement of it enforceable in accordance with the terms hereof and thereof.

 

3.                                      Counterparts.  This Joinder Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement.

 

4.                                      Signature and Delivery.  Each of Abbott Subsidiary and AbbVie Subsidiary acknowledges that it may execute this Joinder Agreement by manual, stamp or mechanical signature, and that delivery of an executed counterpart of a signature page to this Joinder Agreement (whether executed by manual, stamp or mechanical signature) by facsimile or by email in portable document format (PDF) shall be effective as delivery of such executed counterpart of this Joinder Agreement.  Each of Abbott Subsidiary and AbbVie Subsidiary expressly adopts and confirms a stamp or mechanical signature (regardless of whether delivered in person, by mail, by courier, by facsimile or by email in portable document format (PDF)) made in its respective name as if it were a manual signature delivered in person, agrees that it shall not assert that any such signature or delivery is not adequate to bind it to the same extent as if it were signed manually and delivered in person and agrees that, at the reasonable request of the other party to this Joinder Agreement at any time, it shall as promptly as reasonably practicable cause this Joinder Agreement to be manually executed (any such execution to be as of the date of the initial date hereof) and delivered in person, by mail or by courier.

 

5.                                      Notices.  All Notices under this Joinder Agreement and the Ex-US TSA shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by overnight courier service, by facsimile with receipt confirmed (followed by delivery of an original via overnight courier service) or by registered or certified mail (postage prepaid, return receipt requested) to the respective Parties at the following addresses (or at such other address for a Party as shall be specified in a Notice):

 

If to Abbott Subsidiary:

 

Abbott Laboratories
 100 Abbott Park Road
 Abbott Park, Illinois 60064-6020
 Attn: Divisional Vice President, Abbott Transition Organization

Facsimile: (847) 938-5313

 

2











 

with a copy (which shall not constitute Notice) to:

 

[Name of Abbott Subsidiary]

[Address]

Attn:  Financial Director

 

If to AbbVie Subsidiary:

 

AbbVie Inc. 
 1 North Waukegan Road
 North Chicago, Illinois 60064
 Attn: Vice President, Strategic Initiative

Facsimile: (847) 937-4330

 

with a copy (which shall not constitute Notice) to:

 

[Name of AbbVie Subsidiary]

[Address]

Attn:  Financial Director

 

Abbott Subsidiary and AbbVie Subsidiary may, by Notice to the other party to this Joinder Agreement, change the address to which their respective copy of any such Notice is to be given.

 

6.                                      Headings.  The Section headings contained in this Joinder Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Joinder Agreement.

 

7.                                      Governing Law. This Joinder Agreement shall be governed by and construed and interpreted in accordance with the Laws of the State of Delaware, irrespective of the choice of Laws principles of the State of Delaware, as to all matters, including matters of validity, construction, effect, enforceability, performance and remedies.

 

8.                                      Amendment.  No provisions of this Joinder Agreement shall be deemed amended, supplemented or modified unless (a) Abbott and AbbVie have agreed in writing to such amendment, supplement or modification; and (b) such amendment, supplement or modification is in writing and signed by an authorized representative of each of Abbott Subsidiary and AbbVie Subsidiary; provided, however, that the prior written agreement of Abbott and AbbVie shall not be required if the amendment, supplement or modification relates solely to the amendment, supplement or modification to Schedule 1 hereto as contemplated by the Ex-U.S. TSA.  Promptly following any amendment to Schedule 1 hereto, Abbott Subsidiary and AbbVie Subsidiary shall deliver a copy of such amendment to Abbott and AbbVie.

 

9.                                      Relationship to Ex-U.S. TSA.  This Joinder Agreement shall be deemed to be part of, and a modification to, the Ex-U.S. TSA and shall be governed by all the terms and provisions thereof, which terms are incorporated herein by reference, are ratified and confirmed and shall continue in full force and effect as a valid and binding agreement of Abbott Subsidiary and AbbVie Subsidiary enforceable against each of Abbott Subsidiary and AbbVie Subsidiary.

 

* * * * *

 

3











 

IN WITNESS WHEREOF, Abbott Subsidiary and AbbVie Subsidiary have caused this Joinder Agreement to be executed by their duly authorized representatives.

 

 

	
ABBOTT [               ]
    	
 
    	
ABBVIE   [                   ]
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
 
    	
By:
    	
 
    	
 
    
	
 
    	
Name:
    	
Thomas   C. Freyman
    	
 
    	
 
    	
Name:
    	
William   J. Chase
    
	
 
    	
Its:
    	
Authorized   Representative
    	
 
    	
 
    	
Its:
    	
Authorized   Representative
    


 

[Signature Page to Joinder Agreement to Ex-U.S. Transition Services Agreement]

 











 

Schedule 1

Services — Overview

 

Provider: [Abbott Subsidiary]

Recipient: [AbbVie Subsidiary]

 

	
Initial   Services
    	
 
    	
Commencement Date
    	
 
    	
Early Termination
   Date
    	
 
    	
Date of Expiration of
   Service Extension
   Period
    
	
Other   Mg. Costs
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Quality   Assurance
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Distribution   — Order Entry
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Distribution   — Warehousing/Log
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Other   Charges to COGS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Regulatory   Affairs
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Medical   Affairs
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Pharmacovigilance
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Development
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Other   R&D / Medical
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Advertising   / Marketing
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Sales   Force Support
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Acctg,   Reporting & Financial Services
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Financial   Planning & Analysis
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Information   Technology
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Office   Space, Facilities & Related
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Other   General Administrative
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    


 

Schedule 1 - i











 

Provider: [AbbVie Subsidiary]

Recipient: [Abbott Subsidiary]

 

	
Initial   Services
    	
 
    	
Commencement Date
    	
 
    	
Early Termination
   Date
    	
 
    	
Date of Expiration of
   Service Extension
   Period
    
	
Other   Mg. Costs
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Quality   Assurance
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Distribution   — Order Entry
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Distribution   — Warehousing/Log
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Other   Charges to COGS
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Regulatory   Affairs
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Medical   Affairs
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Pharmacovigilance
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Development
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Other   R&D / Medical
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Advertising   / Marketing
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Sales   Force Support
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Acctg,   Reporting & Financial Services
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Financial   Planning & Analysis
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Information   Technology
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Office   Space, Facilities & Related
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Other   General Administrative
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    


 

Schedule 1 - ii